Literature DB >> 29464896

Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

George V Rebec1.   

Abstract

AIMS: This review summarizes evidence for dysfunctional connectivity between cortical and striatal neurons in Huntington's disease (HD), a fatal neurodegenerative condition caused by a single gene mutation. The focus is on data derived from recording of electrophysiological signals in behaving transgenic mouse models. DISCUSSIONS: Firing patterns of individual neurons and the frequency oscillations of local field potentials indicate a disruption in corticostriatal processing driven, in large part, by interactions between cells that contain the mutant gene rather than the mutant gene alone. Dysregulation of glutamate, an excitatory amino acid released by cortical afferents, plays a key role in the breakdown of corticostriatal communication, a process modulated by ascorbate, an antioxidant vitamin found in high concentration in striatum. Up-regulation of glutamate transport by drug administration or viral-vector delivery improves ascorbate homeostasis and neurobehavioral processing in HD mice. Further analysis of electrophysiological data, including the use of sophisticated computational strategies, is required to discern how behavioral demands modulate the flow of corticostriatal information and its disruption by HD.
CONCLUSIONS: Long before massive cell loss occurs, HD impairs the mechanisms by which cortical and striatal neurons communicate. A key problem identified in transgenic animal models is dysregulation of the dynamic changes in extracellular glutamate and ascorbate. Improved understanding of how these neurochemical systems impact corticostriatal communication is necessary before an effective therapeutic strategy can emerge.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington's disease; ascorbate release; behavioral electrophysiology; corticostriatal circuit; functional connectivity; glutamate transport

Mesh:

Substances:

Year:  2018        PMID: 29464896      PMCID: PMC6489880          DOI: 10.1111/cns.12828

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  108 in total

1.  Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease.

Authors:  Sebastien Cayzac; Sebastien Delcasso; Vietminh Paz; Yannick Jeantet; Yoon H Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

2.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

Review 3.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

Review 4.  Distributed modular architectures linking basal ganglia, cerebellum, and cerebral cortex: their role in planning and controlling action.

Authors:  J C Houk; S P Wise
Journal:  Cereb Cortex       Date:  1995 Mar-Apr       Impact factor: 5.357

5.  Contrasting the Role of xCT and GLT-1 Upregulation in the Ability of Ceftriaxone to Attenuate the Cue-Induced Reinstatement of Cocaine Seeking and Normalize AMPA Receptor Subunit Expression.

Authors:  Amber L LaCrosse; Sinead M O'Donovan; Marian T Sepulveda-Orengo; Robert E McCullumsmith; Kathryn J Reissner; Marek Schwendt; Lori A Knackstedt
Journal:  J Neurosci       Date:  2017-05-11       Impact factor: 6.167

6.  Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task.

Authors:  Adriano B L Tort; Mark A Kramer; Catherine Thorn; Daniel J Gibson; Yasuo Kubota; Ann M Graybiel; Nancy J Kopell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

7.  Abnormal motor cortex excitability in preclinical and very early Huntington's disease.

Authors:  Sven Schippling; Susanne A Schneider; Khailash P Bhatia; Alexander Münchau; John C Rothwell; Sarah J Tabrizi; Michael Orth
Journal:  Biol Psychiatry       Date:  2009-02-07       Impact factor: 13.382

Review 8.  Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.

Authors:  Morgana Moretti; Daiane Bittencourt Fraga; Ana Lúcia S Rodrigues
Journal:  CNS Neurosci Ther       Date:  2017-10-04       Impact factor: 5.243

9.  Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.

Authors:  George V Rebec
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

10.  Current understanding of the glial response to disorders of the aging CNS.

Authors:  Roger A Barker; Francesca Cicchetti
Journal:  Front Pharmacol       Date:  2012-05-28       Impact factor: 5.810

View more
  11 in total

1.  Regional differences in dopamine release in the R6/2 mouse caudate putamen.

Authors:  Sam V Kaplan; Ryan A Limbocker; Beth Levant; Michael A Johnson
Journal:  Electroanalysis       Date:  2018-03-30       Impact factor: 3.223

Review 2.  The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington's Disease.

Authors:  Abraham Rosas-Arellano; Argel Estrada-Mondragón; Ricardo Piña; Carola A Mantellero; Maite A Castro
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

Review 3.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

Review 4.  Dysfunction of the corticostriatal pathway in autism spectrum disorders.

Authors:  Wei Li; Lucas Pozzo-Miller
Journal:  J Neurosci Res       Date:  2019-11-22       Impact factor: 4.164

Review 5.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

6.  Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic Q175 Huntington's Disease Mice.

Authors:  Joshua W Callahan; David L Wokosin; Mark D Bevan
Journal:  J Neurosci       Date:  2022-01-20       Impact factor: 6.709

Review 7.  D1R- and D2R-Medium-Sized Spiny Neurons Diversity: Insights Into Striatal Vulnerability to Huntington's Disease Mutation.

Authors:  Guendalina Bergonzoni; Jessica Döring; Marta Biagioli
Journal:  Front Cell Neurosci       Date:  2021-02-10       Impact factor: 5.505

Review 8.  Significant Association Between Huntingtin Gene Mutation and Prevalence of Hopelessness, Depression and Anxiety Symptoms.

Authors:  Adelė Butėnaitė; Robertas Strumila; Aistė Lengvenytė; Indrė Kotryna Pakutkaitė; Aušra Morkūnienė; Aušra Matulevičienė; Edgaras Dlugauskas; Algirdas Utkus
Journal:  Acta Med Litu       Date:  2021-01-21

Review 9.  Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases.

Authors:  Thomas McGrath; Richard Baskerville; Marcelo Rogero; Linda Castell
Journal:  Nutrients       Date:  2022-02-22       Impact factor: 5.717

10.  Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2.

Authors:  María E Prados; Alejandro Correa-Sáez; Juan D Unciti-Broceta; Martín Garrido-Rodríguez; Carla Jimenez-Jimenez; Massimiliano Mazzone; Alberto Minassi; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Neurotherapeutics       Date:  2021-08-02       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.